Brief: Appili Therapeutics Inc - Phase 3 PRESECO Clinical Trial Did Not Achieve Statistical Significance On Primary Endpoint
12/11/2021 12:39
Nov 12 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS INC - PHASE 3 PRESECO (PREVENTING
SEVERE
COVID-19) CLINICAL TRIAL DID NOT ACHIEVE STATISTICAL
SIGNIFICANCE ON PRIMARY ENDPOINT
* APPILI THERAPEUTICS INC - ADDITIONAL ANALYSES OF TRIAL
DATA ARE
ONGOING
* APPILI THERAPEUTICS PROVIDES UPDATE ON PHASE 3 PRESECO
CLINICAL
TRIAL EVALUATING AVIGAN/REEQONUS
Source text for Eikon: ID:nBw5s1Tnka
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez